ADVANCING INNOVATION

Science, at its most meaningful, is defined not only by what it makes possible, but by what it ultimately delivers. For Syngene, this principle is shaped by a single, enduring approach: translating scientific capability into outcomes that matter.

In a global healthcare environment marked by rising complexity, increasing disease burden, and continued pressure on access and affordability, innovation must move beyond discovery to application. Syngene's role as a global Contract Research, Development and Manufacturing Organization (CRDMO) is anchored in enabling this transition, supporting the progression of molecules from early research through development to commercial-scale manufacturing.

Meaningful progress depends on deliberate choices: strengthening core platforms, prioritizing relevant capabilities, and aligning efforts to areas of enduring impact. During the year, we continued to advance this journey through a disciplined operating model, enhanced capabilities, deeper partnerships, and sustained progress on our Environmental, Social and Governance (ESG) and Corporate Social Responsibility (CSR) commitments.

Integration across biology, chemistry, data science, and process engineering further strengthens this model, enabling seamless execution. By combining scientific expertise with robust processes, we ensure consistency, quality, and reliability across programs. A strong emphasis on customer centricity keeps our solutions closely aligned with partner needs, fostering responsiveness and long-term collaboration.

Science for People reflects our belief that innovation must be grounded in human consequence. It asks us to think beyond timelines and deliverables and orient what we do to the lives that our work touches. That orientation gives us purpose and shapes how we grow, how we partner and how we lead.